Bioatla Inc Cash Flow Conversion Efficiency
Bioatla Inc cash flow conversion efficiency. Based on the latest financial reports, Bioatla Inc (BCAB) has a cash flow conversion efficiency ratio of 0.141x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.27 Million) by net assets ($-37.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bioatla Inc (2018–2025)
Cash flow conversion efficiency of Bioatla Inc from 2018 to 2025. This chart illustrates how Bioatla Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BCAB share price today for real-time trading data and today's change.
Bioatla Inc Cash Flow Conversion Ratio Explained
Bioatla Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bioatla Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioatla Inc ranked by their cash flow conversion efficiency. Also see how much is Bioatla Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Henry Boot PLC
LSE:BOOT
|
-0.039x |
|
UMT United Mobility Technology AG
XETRA:UMD
|
0.141x |
|
Dongbu Corp
KO:005965
|
0.058x |
|
Aptevo Therapeutics Inc
NASDAQ:APVO
|
-0.903x |
|
Smiths News PLC
LSE:SNWS
|
2.916x |
|
20/20 Biolabs, Inc. Common Stock
NASDAQ:AIDX
|
-4.946x |
|
Geekco Technologies Corp
V:GKO
|
0.017x |
|
GENERIC GOLD CORP.
F:1WD
|
N/A |
Annual Cash Flow Conversion Efficiency for Bioatla Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bioatla Inc from 2018 to 2025. Review Bioatla Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-36.19 Million | $-48.20 Million | 1.332x | +126.41% |
| 2024-12-31 | $14.27 Million | $-71.94 Million | -5.043x | -242.63% |
| 2023-12-31 | $70.67 Million | $-104.02 Million | -1.472x | -193.54% |
| 2022-12-31 | $180.34 Million | $-90.42 Million | -0.501x | -69.90% |
| 2021-12-31 | $210.82 Million | $-62.21 Million | -0.295x | -70.54% |
| 2020-12-31 | $209.97 Million | $-36.33 Million | -0.173x | -200.49% |
| 2019-12-31 | $-56.01 Million | $-9.64 Million | 0.172x | -86.13% |
| 2018-12-31 | $-28.45 Million | $-35.32 Million | 1.242x | -- |
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); a… Read more